Global Antidiabetic Biguanides Market Size By Type (Metformin IR, Metformin SR), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Antidiabetic Biguanides Market was valued at USD 3.1 billion in 2023 and is projected to reach USD 5.4 billion by 2031, growing at a CAGR of 7.4% during the forecast period from 2023 to 2031. The market's expansion is fueled by the increasing prevalence of type 2 diabetes, growing awareness of early diagnosis and disease management, and the affordability and efficacy of biguanide-based therapies such as metformin. These medications are considered a frontline treatment for managing blood glucose levels in type 2 diabetes, making them indispensable in global treatment protocols.

Drivers:

1. Rising Prevalence of Type 2 Diabetes:

The increasing incidence of diabetes globally, driven by aging populations, sedentary lifestyles, and rising obesity rates, is a major driver. Biguanides, particularly metformin, remain a preferred first-line therapy due to their proven safety, effectiveness, and cost-efficiency.

2. Favorable Clinical Guidelines and High Prescriber Confidence:

Global clinical guidelines consistently recommend biguanides as the initial treatment for type 2 diabetes. This has led to sustained demand among prescribers and patients, further supporting market stability.

3. Expanding Access to Generic Metformin:

The widespread availability of generic versions has enhanced accessibility, particularly in emerging markets, boosting adoption in low- and middle-income countries.

Restraints:

1. Gastrointestinal Side Effects and Intolerance:

Metformin and other biguanides can cause gastrointestinal discomfort, including nausea and diarrhea, leading to non-compliance or dose reduction, which can limit effectiveness.

2. Emergence of Newer Antidiabetic Classes:

The rise of newer, more advanced therapies such as SGLT2 inhibitors and GLP-1 receptor agonists, which offer additional cardiovascular or weight loss benefits, may gradually reduce biguanides’ market share in certain segments.

Opportunity:

1. Untapped Rural and Low-Income Markets:

There are significant opportunities in underpenetrated markets where affordability is a key factor. Metformin’s low cost makes it an ideal candidate for large-scale public health programs.

2. Combination Therapy Demand:

The demand for fixed-dose combination drugs including metformin is growing, offering convenience and improved patient adherence. This trend is expected to open new revenue channels for manufacturers.

Market by System Type Insights:

By drug formulation, Immediate-Release (IR) Biguanides dominated the market in 2023 due to their long-standing use and cost-effectiveness. However, Extended-Release (ER) Biguanides are gaining traction, especially in developed regions, due to improved gastrointestinal tolerability and once-daily dosing that enhances patient compliance.

Market by End-use Insights:

The Hospitals and Clinics segment led the market in 2023, as these facilities serve as primary treatment hubs for diabetes. Additionally, the Retail Pharmacies segment is projected to witness the highest growth during the forecast period, driven by the rising demand for over-the-counter metformin and increased access in emerging economies.

Market by Regional Insights:

Asia-Pacific held the largest share of the global antidiabetic biguanides market in 2023, propelled by a high diabetes burden, favorable government policies, and increasing healthcare access in countries like India and China. North America followed, supported by strong healthcare infrastructure and growing use of extended-release formulations. Meanwhile, Latin America and the Middle East & Africa are poised for significant growth, driven by urbanization, dietary shifts, and public health initiatives targeting diabetes management.

Competitive Scenario:

Key players in the global antidiabetic biguanides market include Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Novartis AG, Sun Pharmaceutical Industries Ltd., Sanofi S.A., Aurobindo Pharma, and Apotex Inc. These companies are focused on developing high-purity formulations, expanding into emerging markets, and innovating combination therapies to strengthen their foothold.

Key developments include:

In 2023, Teva expanded its metformin product line with a new ER formulation targeting European markets.

In 2024, Novartis partnered with health agencies in Asia-Pacific to expand access to affordable metformin-based treatments.

In 2025, Merck launched a co-packaged fixed-dose combination therapy including metformin and a DPP-4 inhibitor, aimed at improving glycemic control in early-stage diabetes patients.

Scope of Work – Global Antidiabetic Biguanides Market

Key Market Developments:

2023: Teva launched a generic extended-release metformin product in the European market, expanding its diabetes portfolio.

2024: Novartis initiated a partnership program with Southeast Asian nations to improve biguanide drug availability.

2025: Merck introduced a co-packaged therapy combining metformin and linagliptin for enhanced glycemic control in early-stage diabetes.

FAQs:

What is the current market size of the Global Antidiabetic Biguanides Market?

The market was valued at USD 3.1 billion in 2023.

What is the major growth driver of the Global Antidiabetic Biguanides Market?

Rising prevalence of type 2 diabetes and the widespread use of metformin as a first-line treatment.

Which is the largest region during the forecast period in the Global Antidiabetic Biguanides Market?

Asia-Pacific is expected to remain the largest region throughout the forecast period.

Which segment accounted for the largest market share in the Global Antidiabetic Biguanides Market?

Immediate-Release Biguanides held the largest market share in 2023.

Who are the key market players in the Global Antidiabetic Biguanides Market?

Merck & Co., Teva, Novartis, Bristol Myers Squibb, Sanofi, and Aurobindo Pharma are among the major players.